This retrospective study analyzed 11,009 WBCT scans from 4,987 patients at a single high-volume foot and ankle center over 5.6 years. It compares radiation dose, image acquisition time, and institutional cost against the conventional radiograph-plus-CT protocol used the year before WBCT adoption. The central question: does WBCT actually deliver on its proposed advantages when deployed at scale?
The two arguments most often used against WBCT adoption — higher radiation exposure and prohibitive cost. Are addressed directly by this dataset, and neither holds at a high-volume center that previously relied on conventional CT for complex deformity workup.
When evaluating whether to advocate for WBCT at your institution, the dose argument depends entirely on your current CT utilization. If your department frequently orders conventional CT for hindfoot, midfoot, or multi-location pathology, switching to WBCT will reduce cumulative dose because CT delivers 6× the radiation of WBCT. If you rarely order CT, WBCT actually increases dose compared to plain radiographs alone.
The financial case is more consistent: time savings dominate the cost model, and even with only 15% of patients billable, this institution achieved a 61-fold increase in annual profit. The break-even on device acquisition occurred within the first year.
One caveat the authors flag: radiation dose values were projected from phantom measurements, not measured directly in patients, so the reported µSv figures are estimates. All five authors are paid consultants for WBCT device manufacturers. A real conflict the authors disclose but acknowledge may influence interpretation.
This retrospective study analyzed 11,009 WBCT scans from 4,987 patients at a single high-volume foot and ankle center over 5.6 years. It compares radiation dose, image acquisition time, and institutional cost against the conventional radiograph-plus-CT protocol used the year before WBCT adoption. The central question: does WBCT actually deliver on its proposed advantages when deployed at scale?
The two arguments most often used against WBCT adoption — higher radiation exposure and prohibitive cost. Are addressed directly by this dataset, and neither holds at a high-volume center that previously relied on conventional CT for complex deformity workup.
When evaluating whether to advocate for WBCT at your institution, the dose argument depends entirely on your current CT utilization. If your department frequently orders conventional CT for hindfoot, midfoot, or multi-location pathology, switching to WBCT will reduce cumulative dose because CT delivers 6× the radiation of WBCT. If you rarely order CT, WBCT actually increases dose compared to plain radiographs alone.
The financial case is more consistent: time savings dominate the cost model, and even with only 15% of patients billable, this institution achieved a 61-fold increase in annual profit. The break-even on device acquisition occurred within the first year.
One caveat the authors flag: radiation dose values were projected from phantom measurements, not measured directly in patients, so the reported µSv figures are estimates. All five authors are paid consultants for WBCT device manufacturers. A real conflict the authors disclose but acknowledge may influence interpretation.